Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 9/20 | 0.48 |
| ▸ | LPAR2 | Q9HBW0 | 8/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.48 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.45 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.45 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18686723 | 0.87 | LPAR3 (0.54) | LPAR3LPAR2LPAR1TSHR | |
| SCHEMBL12282756 | 0.85 | LPAR3 (0.50) | LPAR3LPAR2LPAR1GABBR2GABBR1 | |
| SCHEMBL18272681 | 0.83 | LPAR3 (0.69) | LPAR3LPAR2LPAR1 | |
| SCHEMBL6956386 | 0.83 | LPAR3 (0.42) | LPAR3LPAR2LPAR1GABBR2GABBR1 | |
| SCHEMBL18715371 | 0.83 | LPAR3 (0.69) | LPAR3LPAR2LPAR1 | |
| SCHEMBL27935494 | 0.83 | LPAR3 (0.69) | LPAR3LPAR2LPAR1 | |
| SCHEMBL6957697 | 0.83 | LPAR3 (0.42) | LPAR3LPAR2LPAR1GABBR2GABBR1 | |
| SCHEMBL15281699 | 0.83 | LPAR3 (0.69) | LPAR3LPAR2LPAR1 | |
| SCHEMBL28224948 | 0.83 | — | — | |
| SCHEMBL23178880 | 0.82 | LPAR3 (0.56) | LPAR3LPAR2LPAR1GABBR2GABBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2023-01-05 | — | — | US | disclosed |
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-04-01 | — | — | US | disclosed |
| US-20170137815-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170137815-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS INC (US) | 2017-05-18 | — | — | US | disclosed |
| US-20130253168-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | SIRNA THERAPEUTICS, INC. | 2013-09-26 | — | — | US | disclosed |
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093725-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | LPAR3 747/4885LPAR2 1208/4885LPAR1 1327/4885 |
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | LPAR3 2459/4885LPAR2 2914/4885LPAR1 2250/4885 |
| US-20130041133-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | PHAX, NSUN3, NSUN2 | LPAR3 507/4885LPAR2 628/4885LPAR1 519/4885 |
| US-20130253168-A1 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES | ALKBH1, ADAR, RNGTT | LPAR3 586/4885LPAR2 725/4885LPAR1 559/4885 |
| US-20230002767-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | MUC1, ALG1, RNASE1 | LPAR3 331/4885LPAR2 642/4885LPAR1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.